Mereo BioPharma (MREO) furnishes Q3 2025 results press release

Mereo BioPharma Group plc (MREO) furnished an update under Item 2.02, announcing financial results for the third quarter ended September 30, 2025, and recent corporate highlights.

Rhea-AI Filing Summary

Mereo BioPharma Group plc (MREO) furnished an update under Item 2.02, announcing financial results for the third quarter ended September 30, 2025, and recent corporate highlights. The full details are contained in a press release dated November 10, 2025, furnished as Exhibit 99.1.

The company noted that the information in Item 2.02 (including Exhibit 99.1) is being furnished, not filed, under the Exchange Act. MREO’s American Depositary Shares, each representing five ordinary shares, trade on The Nasdaq Stock Market LLC under the symbol MREO.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did MREO announce in this 8-K?

The company furnished financial results for the third quarter ended September 30, 2025, along with recent corporate highlights.

Where can I find MREO’s detailed Q3 2025 results?

Details are in the press release dated November 10, 2025, furnished as Exhibit 99.1.

Is the Q3 2025 information deemed filed with the SEC?

No. The Item 2.02 information (including Exhibit 99.1) is furnished, not filed under the Exchange Act.

What is MREO’s trading symbol and listing?

American Depositary Shares trade on The Nasdaq Stock Market LLC under the symbol MREO.

What do MREO’s ADSs represent?

Each American Depositary Share represents five ordinary shares with nominal value £0.003 per share.

Which exhibits are included in this report?

Exhibit 99.1 (Press Release, dated November 10, 2025) and Exhibit 104 (Cover Page Interactive Data File).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/10/2025 - 04:20 PM Learn about SEC filing dates

0001719714FalsetrueX000-00000000001719714us-gaap:CommonStockMember2025-11-102025-11-1000017197142025-11-102025-11-100001719714dei:AdrMember2025-11-102025-11-10

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2025

MEREO BIOPHARMA GROUP PLC

(Exact name of registrant as specified in its charter)

England and Wales		001-38452		Not Applicable
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

4th Floor, One Cavendish Place,

London, W1G 0QF

United Kingdom

(Address of principal executive offices, including zip code)

+44-333-023-7300

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
American Depositary Shares, each representing five Ordinary Shares, par value £0.003 per share		MREO		The Nasdaq Stock Market LLC
Ordinary Shares, nominal value £0.003 per share*		*		The Nasdaq Stock Market LLC

*Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 10, 2025, Mereo BioPharma Group plc announced its financial results for the third quarter ended September 30, 2025 and provided recent corporate highlights. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 2.02 of this Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description of Exhibit
99.1	Press Release, dated November 10, 2025.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	MEREO BIOPHARMA GROUP PLC
Date: November 10, 2025	By:	/s/ Christine Fox
		Name:	Christine Fox
		Title:	Chief Financial Officer